证券代码：002940 证券简称：昂利康 公告编号：2025-071 （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 浙江昂利康制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召 开第四届董事会第六次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金及股票回购专项贷款以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激励。本次回 购股份的资金总额不低于人民币5,000万元（含）且不超过人民币7,000万元（含）， 回购价格不超过人民币 21.07 元/股（含）。具体回购股份的数量以公司实际回购 的股份数量为准。本次回购股份的实施期限为自董事会审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司于 2024 年 11 月 5 日、2024 年 11 月 8 日在指定信息披露媒体《证券时报》及巨潮资 ...

Core Viewpoint - The stock of Anglikang has shown significant volatility, with a year-to-date increase of 192.23%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported operating revenue of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% year-on-year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 50.49% to 18,500, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.44 million shares, and Guangfa Technology Innovation Mixed A, holding 6.16 million shares [3].

证券日报网讯 9月24日晚间，昂利康发布公告称，公司于2025年9月23日召开第四届董事会第十一次会 议，审议通过了《关于第一期员工持股计划存续期展期的议案》，同意将公司第一期员工持股计划的存 续期展期12个月，即存续期展期至2026年11月2日。 （编辑 楚丽君） ...

证券代码：002940 证券简称：昂利康 公告编号：2025-070 1 为 4,331,150 股，占公司目前总股本的 2.15%。具体内容详见公司在指定信息披 露媒体《证券时报》及巨潮资讯网（www.cninfo.com.cn）上刊载的相关公告。 浙江昂利康制药股份有限公司 关于第一期员工持股计划存续期展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日召 开第四届董事会第十一次会议，审议通过了《关于第一期员工持股计划存续期展 期的议案》，同意将公司第一期员工持股计划的存续期展期 12 个月，即存续期展 期至 2026 年 11 月 2 日。 一、本次员工持股计划基本情况 公司于 2022 年 4 月 11 日召开第三届董事会第十三次会议、第三届监事会第 十次会议，于 2022 年 5 月 11 日召开 2021 年度股东大会，审议通过了《关于< 浙江昂利康制药股份有限公司第一期员工持股计划（草案）>及其摘要的议案》 等员工持股相关议案。具体内容详见公司于 2022 年 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-069 浙江昂利康制药股份有限公司 关于第四届董事会第十一次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江昂利康制药股份有限公司（以下简称"公司"）第四届董事会第十一次 会议（以下简称"会议"）通知于 2025 年 9 月 18 日以专人送达、邮件等方式发 出，会议于 2025 年 9 月 23 日以通讯表决的方式召开。本次会议的应表决董事 7 人，实际参与表决董事 7 人。会议由董事长方南平先生主持。本次会议的召集、 召开符合《中华人民共和国公司法》和《公司章程》的规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过了《关于第一期员工持股计划存续期展期的议案》 基于对公司未来发展的信心和对公司价值的认可，经公司第一期员工持股计 划持有人会议表决并经董事会审议通过，同意将公司第一期员工持股计划的存续 期展期 12 个月，即存续期延长至 2026 年 11 月 2 日。 该议案已经公司薪酬与考核委员会审议通过。 （2）股份转换时间 本次 H 股" ...

每经AI快讯，昂利康（SZ 002940，收盘价：39.15元）9月24日晚间发布公告称，公司第四届第十一次 董事会会议于2025年9月23日以通讯表决的方式召开。会议审议了《关于第一期员工持股计划存续期展 期的议案》等文件。 每经头条（nbdtoutiao）——"9·24"一周年，A股总市值破116万亿元！四大变革重塑中国资本市场新生 态 （记者 曾健辉） 2025年1至6月份，昂利康的营业收入构成为：医药制造业占比100.0%。 截至发稿，昂利康市值为79亿元。 ...

Core Viewpoint - The stock of Anglikang has shown significant volatility, with a year-to-date increase of 200.05%, but recent declines in the last five, twenty, and sixty trading days indicate potential market concerns [1][2]. Company Overview - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition of Anglikang includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported operating revenue of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% year-on-year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, Anglikang had 18,500 shareholders, an increase of 50.49% from the previous period, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.44 million shares, and Guangfa Technology Innovation Mixed A, holding 6.16 million shares [3].

Summary of the Conference Call for Angli Kang Company Overview - **Company**: Angli Kang - **Industry**: Pharmaceutical and Biotechnology Key Points and Arguments Innovation and Drug Development - Angli Kang is addressing its lack of experience in innovative drugs through collaborative models, focusing on core new drugs such as Affinity 1,618 (a first-in-class drug expected to have phase I data by mid-2026) and a CD47-targeting antibody drug expected to file IND in Australia and domestically within the year [2][4] - The company has adopted a tiered transition strategy in its innovation transformation, where existing generic drugs provide short-term performance support, modified new drugs build a mid-term moat, and innovative drugs open long-term growth opportunities [3] Core New Drugs Progress - Affinity 1,618 is currently in phase I clinical trials, with data expected in mid-2026. The second core new drug, a tumor microenvironment-activated IGG1 subtype targeting CD47, is expected to file IND in Australia and domestically within the year [4][5] Market Potential - Once commercialized, Affinity 1,618 is projected to achieve sales exceeding 3 billion yuan, indicating significant market potential and substantial valuation elasticity based on a 3x price-to-sales (PS) estimate [6] Business Segments and Risks - The company has cleared existing risks in its formulation business, with multiple specialty generic drugs launched and successfully winning bids in centralized procurement, which is expected to drive medium to long-term growth [7] - The raw materials and specialty intermediates business, primarily focused on cephalosporins, is currently affected by weak domestic antibiotic demand but is expected to stabilize and recover starting in 2026 [7] Financial Performance and Growth Expectations - Angli Kang's main business profits are approximately 120 million yuan, with an expected annual growth rate of 30-50%. The combination of innovative drug potential and continuous introduction of new pipelines suggests strong future performance growth [8] Additional Important Insights - The high-purity plant-derived cholesterol and its derivatives provide stable and substantial cash flow, enhancing the company's financial stability [7]

Core Viewpoint - On September 15, Angli康's stock price dropped by 5.02%, closing at 43.17 yuan per share, with a trading volume of 656 million yuan and a turnover rate of 8.04%, resulting in a total market capitalization of 8.709 billion yuan [1] Company Overview - Zhejiang Angli康 Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, and was established on December 30, 2001, with its listing date on October 23, 2018 [1] - The company's main business involves the research, development, production, and sales of chemical raw materials and formulations [1] - The revenue composition of the main business is as follows: formulations 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Shareholder Information - Among Angli康's top ten circulating shareholders, a fund under ICBC Credit Suisse Asset Management, namely ICBC Frontier Medical Stock A (001717), entered the top ten in the second quarter, holding 3.8022 million shares, accounting for 2.05% of circulating shares [2] - The estimated floating loss for this fund today is approximately 8.6691 million yuan [2] - ICBC Frontier Medical Stock A was established on February 3, 2016, with a latest scale of 9.33 billion yuan, and has achieved a return of 38.2% this year, ranking 934 out of 4223 in its category [2] - Over the past year, the fund has returned 48.29%, ranking 2139 out of 3803 in its category, and has achieved a cumulative return of 263.6% since inception [2] - The fund manager, Zhao Bei, has a tenure of 10 years and 305 days, with a total asset scale of 16.425 billion yuan [2]

Group 1 - The core viewpoint of the news is that Anglikon has seen a significant increase in its stock price, rising by 5.01% to reach 43.39 yuan per share, with a trading volume of 448 million yuan and a turnover rate of 5.72%, resulting in a total market capitalization of 8.753 billion yuan [1] - Anglikon Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and was established on December 30, 2001. It was listed on October 23, 2018. The company's main business involves the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon is as follows: formulations account for 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Group 2 - From the perspective of fund holdings, Huafu Fund has a significant position in Anglikon, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 150,000 shares, representing 7.52% of the fund's net value, making it the second-largest holding [2] - The Huafu Health and Entertainment Flexible Allocation Mixed A Fund was established on August 4, 2015, with a latest scale of 33.8496 million yuan. Year-to-date returns are 63.49%, ranking 389 out of 8174 in its category; the one-year return is 66.3%, ranking 1688 out of 7981; and since inception, the return is 58.19% [2] - The fund manager of Huafu Health and Entertainment Flexible Allocation Mixed A Fund is Liao Qingyang, who has been in the position for 3 years and 308 days, with a total asset scale of 74.027 million yuan. The best fund return during his tenure is 42.84%, while the worst is -0.06% [2]